Papers published on a yearly basis
Papers
More filters
••
TL;DR: Intensive glycemic control and reduction in serum cholesterol level increase costs and improve health outcomes and the cost-effectiveness ratios for these 2 interventions are comparable with several other frequently adopted health care interventions.
Abstract: CONTEXT
Several treatment interventions can reduce complications of type 2 diabetes, but their relative cost-effectiveness is not known.
OBJECTIVE
To estimate the incremental cost-effectiveness of intensive glycemic control (relative to conventional control), intensified hypertension control, and reduction in serum cholesterol level for patients with type 2 diabetes.
DESIGN, SETTING, AND PATIENTS
Cost-effectiveness analysis of a hypothetical cohort of individuals living in the United States, aged 25 years or older, who were newly diagnosed as having type 2 diabetes. The results of the United Kingdom Prospective Diabetes Study (UKPDS) and other studies were used to create a model of disease progression and treatment patterns. Costs were based on those used in community practices in the United States.
INTERVENTIONS
Insulin or sulfonylurea therapy for intensive glycemic control; angiotensin-converting enzyme inhibitor or beta-blocker for intensified hypertension control; and pravastatin for reduction of serum cholesterol level.
MAIN OUTCOME MEASURES
Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 US dollars) and QALYs were discounted at a 3% annual rate.
RESULTS
The incremental cost-effectiveness ratio for intensive glycemic control is $41 384 per QALY; this ratio increased with age at diagnosis from $9614 per QALY for patients aged 25 to 34 years to $2.1 million for patients aged 85 to 94 years. For intensified hypertension control the cost-effectiveness ratio is -$1959 per QALY. The cost-effectiveness ratio for reduction in serum cholesterol level is $51 889 per QALY; this ratio varied by age at diagnosis and is lowest for patients diagnosed between the ages of 45 and 84 years.
CONCLUSIONS
Intensified hypertension control reduces costs and improves health outcomes relative to moderate hypertension control. Intensive glycemic control and reduction in serum cholesterol level increase costs and improve health outcomes. The cost-effectiveness ratios for these 2 interventions are comparable with those of several other frequently adopted health care interventions.
501 citations
•
11 Feb 2000TL;DR: A monitoring system having at least two components is employed in this paper in order to allow separation of data collection from data processing and display, such separation allows greater flexibility and convenience for the user.
Abstract: Devices and methods are provided for frequently measuring the concentration of an analyte present in a biological system. A monitoring system having at least two components is employed in order to allow separation of data collection from data processing and display. Such separation allows greater flexibility and convenience for the user.
474 citations
•
10 Aug 2001TL;DR: In this article, the authors present methods of formulating analyte data databases, the databases themselves, and methods of manipulating the same, and the resulting databases may be manipulated to determine relationships among the components of the database.
Abstract: The present invention relates to methods of formulating analyte data databases, the databases themselves, and methods of manipulating the same. In one aspect the present invention includes the formulation of analyte data points, derived data, and data attributes databases comprising data points collected using an analyte monitoring device capable of frequent monitoring of analyte concentrations or amounts. Such data points may comprise acquired data (e.g., values corresponding to analyte concentrations or amounts as measured by said analyte monitoring device). These data points are then associated with one or more relevant data attributes. The resulting databases may be manipulated to determine relationships among the components of the database.
453 citations
•
11 May 1999TL;DR: In this article, a method for continuously measuring the concentration of target chemical analytes present in a biological system, and processing analyte-specific signals to obtain a measurement value that is closely correlated with the concentration in the biological system.
Abstract: A method is provided for continually or continuously measuring the concentration of target chemical analytes present in a biological system, and processing analyte-specific signals to obtain a measurement value that is closely correlated with the concentration of the target chemical analyte in the biological system. One important application of the invention involves a method for signal processing in a system for monitoring blood glucose values.
451 citations
•
11 May 1999TL;DR: In this paper, a method and device for measuring the concentration of target chemical analytes present in a biological system is described. But this method does not consider the effect of interfering species on sensor sensitivity.
Abstract: Methods and devices are provided for measuring the concentration of target chemical analytes present in a biological system. Device configuration and/or measurement techniques are employed in order to reduce the effect of interfering species on sensor sensitivity. One important application of the invention involves a method and device for monitoring blood glucose values.
443 citations
Authors
Showing all 136 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bruce A. Buckingham | 69 | 280 | 16586 |
Subbu S. Venkatraman | 55 | 274 | 10851 |
Russell O. Potts | 53 | 92 | 11440 |
H. Peter Chase | 51 | 160 | 7898 |
Carol A. Brenner | 34 | 56 | 5293 |
Janet A. Tamada | 33 | 49 | 6234 |
Timothy C. Dunn | 27 | 62 | 3844 |
Eba Hathout | 23 | 46 | 1607 |
Gary W. Cleary | 20 | 37 | 1486 |
Michael J. Tierney | 19 | 37 | 3574 |
Janet Tamada | 17 | 33 | 2790 |
Michael J. Tierney | 15 | 22 | 1411 |
John G. Morgan | 15 | 24 | 1047 |
Steven Richard Waterhouse | 14 | 17 | 1864 |
Pravin L. Soni | 12 | 17 | 1095 |